Core Insights - Beta Bionics has launched Bionic Insights™, a feature within its Bionic Reports aimed at enhancing treatment recommendations for diabetes patients [1][2] - This innovation positions Beta Bionics as the first insulin pump company to provide advanced intelligent reporting, allowing clinicians to interpret patient data more effectively [2][3] Group 1: Product Features - Bionic Insights offers a structured approach to data by categorizing information into Areas of Success and Areas of Opportunity, enabling clinicians to quickly identify factors influencing glucose outcomes [4][7] - The feature transforms complex data into clear, actionable guidance, facilitating more productive conversations between clinicians and patients [3][5] Group 2: Clinical Impact - The introduction of Bionic Insights is expected to improve glucose control for patients by providing healthcare providers with unprecedented clarity on treatment effectiveness and areas needing support [2][3] - By enhancing the understanding of patient data, Bionic Insights aims to foster better communication and targeted recommendations, ultimately improving patient outcomes [5][6] Group 3: Company Overview - Beta Bionics, headquartered in Irvine, California, is focused on revolutionizing diabetes care through innovative solutions like the iLet Bionic Pancreas, which features a closed-loop algorithm for insulin delivery [6] - The company's mission is to simplify diabetes management and improve the quality of life for individuals living with diabetes [6]

Core Viewpoint - Beta Bionics, Inc. is set to release its first quarter 2026 financial results on April 21, 2026, after market close, followed by a conference call to discuss performance [1]. Company Overview - Beta Bionics, Inc. is a commercial-stage medical device company focused on developing innovative solutions for insulin-requiring individuals with diabetes [2]. - The company utilizes advanced adaptive closed-loop algorithms to enhance diabetes treatment and improve the health and quality of life for people with diabetes [2]. - The iLet Bionic Pancreas is highlighted as the first FDA-cleared insulin delivery device that autonomously determines insulin doses, aiming to improve overall outcomes for a broad population of people with diabetes [2].

Core Viewpoint - Beta Bionics, Inc. is set to present at TD Cowen's 46th Annual Health Care Conference on March 4, 2026, highlighting its advancements in diabetes management solutions [1]. Company Overview - Beta Bionics, Inc. is a commercial-stage medical device company focused on designing, developing, and commercializing innovative solutions for insulin-requiring individuals with diabetes [3]. - The company utilizes advanced adaptive closed-loop algorithms to enhance the treatment of diabetes, aiming to improve health and quality of life for patients [3]. - The iLet Bionic Pancreas is noted as the first FDA-cleared insulin delivery device that autonomously determines insulin doses, potentially improving outcomes for a wide range of diabetes patients [3]. Investor Relations - The company provides a live audio webcast of its presentations, which can be accessed on its website under the "Investors—Events & Presentations" section [2]. - Contact information for investor relations and media inquiries is available, with Blake Beber as the Head of Investor Relations and Karen Hynes as the Vice President of Marketing [4].

Core Viewpoint - Beta Bionics, Inc. reported strong financial results for Q4 and full year 2025, indicating significant growth in the durable insulin pump market and providing guidance for 2026 [1][5][12]. Financial Highlights Fourth Quarter 2025 - Net sales reached $32.1 million, a 57% increase from $20.4 million in Q4 2024 [5][21]. - Durable Medical Equipment (DME) channel net sales were $22.3 million, up 24% from $18.0 million in Q4 2024 [5][21]. - Pharmacy Benefit Plan (PBP) channel net sales surged to $9.8 million, a 295% increase from $2.5 million in Q4 2024 [5][21]. - Gross margin improved to 59.0%, up 179 basis points from 57.2% in Q4 2024 [5][21]. - The installed customer base grew to 35,011 users, a 129% increase from 15,298 in Q4 2024 [5][21]. - New patient starts totaled 5,592, a 37% increase from 4,084 in Q4 2024 [5][26]. Full Year 2025 - Total net sales for the year were $100.3 million, a 54% increase from $65.1 million in 2024 [5][21]. - DME channel net sales for the year were $75.8 million, up 29% from $58.8 million in 2024 [5][21]. - PBP channel net sales reached $24.4 million, a 287% increase from $6.3 million in 2024 [5][21]. - Gross margin for the year was 55.4%, up 29 basis points from 55.1% in 2024 [5][21]. - New patient starts for the year totaled 19,713, a 52% increase from 12,994 in 2024 [5][26]. Strategic Highlights - The company completed its first-in-human Phase 2a feasibility trial for its bihormonal system in New Zealand [5][6]. - An additional Phase 2a feasibility trial is expected to be initiated in the first half of 2026 [5][6]. - The company aims to progress to Phase 2b following the completion of the Phase 2a trial, which is anticipated to be a pivotal trial [5][6]. 2026 Guidance - Estimated total revenue for 2026 is projected to be approximately $130 million to $135 million [12]. - Expected gross margin for 2026 is estimated to be between 55.5% and 57.5% [12]. - The company anticipates that 36% to 38% of new patient starts will be reimbursed through the PBP channel [12].

Core Viewpoint - Beta Bionics, Inc. is set to announce its fourth quarter and full year 2025 financial results on February 17, 2026, after market close, followed by a conference call to discuss performance [1]. Company Overview - Beta Bionics, Inc. is a commercial-stage medical device company focused on developing innovative solutions for insulin-requiring individuals with diabetes, utilizing advanced adaptive closed-loop algorithms [3]. - The company's flagship product, the iLet Bionic Pancreas, is the first FDA-cleared insulin delivery device that autonomously determines insulin doses, aiming to improve health outcomes for a broad population of people with diabetes [3]. Investor Relations - For investor inquiries, Blake Beber serves as the Head of Investor Relations, and can be contacted via email [4]. - Media and public relations are managed by Karen Hynes, Vice President of Marketing, who is also available for contact [4]. Event Details - The conference call and webcast will take place at 4:30 PM Eastern Time (1:30 PM Pacific Time) on February 17, 2026, to review the company's financial performance [1]. - A link to the webcast will be available on the company's website and will be archived for future access [2].

Core Viewpoint - Beta Bionics, Inc. reported preliminary, unaudited financial results for Q4 2025, indicating significant growth in net sales and customer base compared to the previous year [1][6]. Financial Results - Net sales for Q4 2025 are expected to be at least $32.0 million, representing an increase of at least 56% from $20.4 million in Q4 2024 [7]. - Durable Medical Equipment (DME) channel net sales are projected to be at least $22.3 million, up at least 23% from $18.1 million in Q4 2024 [7]. - Pharmacy Benefit Plan (PBP) channel net sales are expected to reach at least $9.7 million, reflecting an increase of at least 308% compared to $2.4 million in Q4 2024 [7]. Customer Metrics - The installed customer base is anticipated to be at least 35,000 users, marking an increase of at least 128% from 15,298 in Q4 2024 [7]. - New patient starts are expected to be at least 5,581, which is an increase of at least 36% compared to 4,084 new patient starts in Q4 2024 [7]. - Approximately 69% of new patient starts are expected to come from multiple daily injections (MDI) [7]. Future Events - The company plans to report its full Q4 and full year 2025 financial results on February 17, 2026, followed by a conference call at 4:30 PM Eastern Time [4].

Core Viewpoint - Beta Bionics, Inc. plans to pre-release its topline fourth quarter 2025 financial results in early January 2026, highlighting its commitment to transparency and investor engagement [1]. Financial Results - The pre-release will cover key metrics including net sales, new patient starts, and the reimbursement percentage of new patient starts through the pharmacy benefit plan (PBP) channel [2]. Investor Engagement - The management team will hold in-person meetings in San Francisco from January 12 to January 14, 2026, to discuss the topline results, inviting investors to register for these meetings [3]. Company Overview - Beta Bionics is a commercial-stage medical device company focused on developing innovative solutions for insulin-requiring individuals with diabetes, utilizing advanced adaptive closed-loop algorithms [4]. - The iLet Bionic Pancreas is noted as the first FDA-cleared insulin delivery device that autonomously determines insulin doses, aiming to improve health outcomes for a broad population of people with diabetes [4].

Core Insights - Beta Bionics, Inc. reported a significant increase in net sales and raised its full-year guidance for 2025, indicating strong growth in its diabetes management solutions [1][7]. Financial Performance - Net sales reached $27.3 million, a 63% increase from $16.7 million in Q3 2024 [5]. - Durable Medical Equipment (DME) channel net sales were $21.0 million, up 45% from $14.5 million in Q3 2024 [5]. - Pharmacy Benefit Plan (PBP) channel net sales surged 178% to $6.2 million from $2.2 million in Q3 2024 [5]. - Gross margin improved to 55.5%, up 212 basis points from 53.4% in Q3 2024 [5]. - The installed customer base grew to 29,419 users, a 162% increase from 11,214 in Q3 2024 [5]. - New patient starts totaled 5,334, a 68% increase from 3,180 in Q3 2024 [5]. - The company reported a loss from operations of $17.0 million, or negative 63% of sales, compared to a loss of $11.0 million or negative 66% of sales in Q3 2024 [5]. Strategic Developments - As of July 1, 2025, Beta Bionics has effective formulary agreements with all major pharmacy benefit managers in the U.S. [5]. - The completion of a glucagon pharmacokinetic-pharmacodynamic trial in Canada supports the development of the glucagon asset for the bihormonal system [5]. - A feasibility trial in New Zealand is expected to be initiated in Q4 2025 to test the bihormonal system in humans [5]. Full Year Guidance - The company estimates total revenue exceeding $96.5 million, up from a previous estimate of $88 million to $93 million [12]. - The expected percentage of new patient starts reimbursed through the PBP channel is revised to 27% to 29%, up from 25% to 28% [12]. - Estimated gross margin is now projected at 54% to 55%, an increase from the previous estimate of 52% to 55% [12].

Core Insights - Beta Bionics, Inc. plans to release its third quarter 2025 financial results on October 28, 2025, after market close [1] - A conference call and webcast will be held on the same day at 4:30 pm Eastern Time [1] Company Overview - Beta Bionics is a commercial-stage medical device company focused on developing innovative solutions for insulin-requiring individuals with diabetes [2] - The company utilizes advanced adaptive closed-loop algorithms to enhance diabetes treatment [2] - The iLet Bionic Pancreas is the first FDA-cleared insulin delivery device that autonomously determines insulin doses, aiming to improve health outcomes for a wide range of diabetes patients [2]

Company Overview - InspireMD, Inc. is a developer of the CGuard® Prime carotid stent system aimed at preventing strokes [1] - The company is publicly traded on Nasdaq under the ticker symbol NSPR [5] Leadership Appointment - Dan Dearen has been appointed to the Board of Directors, bringing nearly 40 years of experience in the medical device and life sciences sectors [1][2] - His previous roles include President, co-Founder, and Chief Financial Officer of Axonics, Inc., which was acquired by Boston Scientific for $3.7 billion in November 2024 [2][3] Strategic Importance - The appointment of Mr. Dearen is seen as timely as InspireMD continues its U.S. commercial launch of the CGuard Prime stent system [2] - The company aims to lead the carotid intervention market and execute its long-term value-creation strategy [2] Market Potential - Mr. Dearen expressed optimism about InspireMD's potential to change the standard of care in vascular medicine and improve patient outcomes [2] - The company utilizes proprietary MicroNet™ mesh technology to enhance the effectiveness of its carotid stenting products [5]